How to Perform Contrast Enhanced Oncologic Staging MRI of Abdomen and Pelvis with a Hepatocyte Specific Agent in a Large Bore MR Scanner: Optimizing Extrahepatic Tumor Evaluation in Neuroendocrine Neoplasms Abstract #2113

Introduction: Liver specific MR contrast agents in neuroendocrine neoplasms (NEN) have shown its advantages in evaluation of hepatic tumor burden. However, a standard scan protocol is insufficient in extrahepatic and especially pelvic tumor evaluation.
Aim(s): To evaluate a MRI shuttle protocol with fast 3D-T1w sequences and hepatospecific contrast (Gd-EOB) to enable imaging abdomen and pelvis in optimal first pass contrast phases in the setting of a large bore MRI scanner with shorter axial field of view.
Materials and methods: 96 patients with NEN of the abdomen were scanned with the first pass (FP) pelvic sequence in a Gd-EOB MRI. We compared pelvic vessel and tissue enhancement between FP and a standard equilibrium (EQ) pelvic sequence. Dynamic liver enhancement between the new protocol including FP pelvic sequence was compared to a standard protocol without additional sequence.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Dr. Uli Fehrenbach

To read results and conclusion, please login ...

Further abstracts you may be interested in

#22 A Case Illustrative of Phenotypic Heterogeneity and Challenges in the Management of Paraganglioma
Introduction: Paragangliomas (PGLs) are extra-adrenal, usually benign, highly vascularized tumors that originate from neural-crest-derived chromaffin cells. These tumors are subdivided as either sympathetic or parasympathetic, depending on their location and catecholamine production. Sympathetic PGLs are situated along the abdominal sympathetic trunk and usually produce catecholamines, whereas parasympathetic PGLs are located in the head and neck, and these usually do not produce catecholamines. PGLs may present as sporadic or inherited tumor syndrome, including MEN 2, with RET germline mutations, von Hippel-Lindau (VHL) disease due to germline mutations in VHL gene, and pheochromocytoma-PGL syndrome. The latter is frequently a hereditary condition and is caused by germline mutations in the SDHB, SDHC, or SDHC genes. Patients with familial PGLs may present at a younger age, often as multifocal tumors, with an increased risk of recurrence and a higher frequency of malignancy in those with SDHB mutations. SDH mutations induce angiogenesis and tumorogenesis through the inhibition of hypoxia-inducible factors (HIF)-propyl hyroxylase. A younger age at onset, malignancy, and a positive family history are clinical parameters of high specificity, but low sensitivity for diagnosis. Genetic analysis for mutations in SDH genes for the patient and family members, and surveillance for the affected patient and family members, are necessary where there are no clear clinical or family indicators for the syndrome. We present a case of a large abdominal malignant PGL in a 20-year-old pt. that went on without clinical detection for at least three years.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohammed Ahmed
#2700 Pancreatic Neuroendocrine Neoplasms and Liver Metastases: When Size Matters
Introduction: Small non-functioning pNENs are low grade indolent tumors, however distant metastases have also been documented in this subset of patients
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: MD Michela Monteleone
#2715 The Role of Serum Concentration Ratio of Neuron-Specific Enolase in the Evaluation of Therapeutic Effect of Neuroendocrine Tumor
Introduction: There has been no good serum biomarker for the evaluation of the therapeutic effect of Neuroendocrine tumors(NET)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Kan Jingbao
Authors: Jingbao K, ...
#2748 CT-Based Radiomics for Prediction of Outcome after Somatostatin Analogues in Patients with Liver Metastases of a Neuroendocrine Tumor: An Exploratory Study
Introduction: Response evaluation and prediction of outcome of a neuroendocrine tumor (NET) remains difficult.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: Femke Staal
#2770 Evaluation of Early Predictors of Metabolic Syndrome in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Introduction: Metabolic syndrome and obesity (MetS) are supposed to have a role in cancer but data analysing their association with GEP-NET are lacking.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD Roberta Modica